Vera Therapeutics grants equity inducement awards to new hires
Vera Therapeutics Inc granted inducement equity awards to new employees under Nasdaq Listing Rule 5635(c)(4). Chief Regulatory Officer Nancy Bowman received 63,011 stock options and 44,987 RSUs, while two other new hires received smaller packages. The awards vest over four years and are subject to continued service.
*this image is generated using AI for illustrative purposes only.
Vera Therapeutics Inc (NASDAQ: VERA) announced on August 7, 2026, that its Compensation Committee granted inducement equity awards to three new employees in accordance with Nasdaq Listing Rule 5635(c)(4). The awards, consisting of non-qualified stock options and restricted stock units (RSUs), were approved as material inducements for employment. Nancy Bowman, M.D., Ph.D., the company’s new Chief Regulatory Officer, received the largest package, followed by two additional unnamed employees.
The Compensation Committee granted the awards on August 3 and August 4, 2026, under the Vera Therapeutics Inc 2024 Inducement Plan. Dr Bowman was awarded options to purchase 63,011 shares of Class A common stock and RSUs underlying 44,987 shares. The two other new employees collectively received options for 5,600 shares and RSUs for 2,800 shares. The exercise prices were set based on the closing trading price of VERA’s Class A common stock on the respective grant dates.
| Recipient | Grant Date | Stock Options | Option Exercise Price | RSUs |
|---|---|---|---|---|
| Nancy Bowman, M.D., Ph.D. | August 3, 2026 | 63,011 shares | $32.23 per share | 44,987 shares |
| Two New Employees | August 4, 2026 | 5,600 shares | $29.95 per share | 2,800 shares |
The vesting schedules differ between the option types. Each stock option will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the applicable vesting commencement date. The remaining 75% will vest monthly over the subsequent 36 months, subject to continued service. In contrast, each RSU award will vest over four years, with 25% of the underlying shares vesting on each anniversary of August 20, also contingent on continued service through the applicable vesting dates.
All awards are subject to the terms and conditions of the Inducement Plan and the specific award agreements executed with each recipient. The grants reflect the company’s strategy to attract key regulatory and operational talent through equity incentives aligned with long-term shareholder value. The exercise prices of $32.23 and $29.95 per share correspond to the market closing prices on August 3 and August 4, 2026, respectively.
What the Numbers Show
The disparity in grant sizes highlights the seniority of Dr Bowman’s role compared to the other new hires. Her total potential equity exposure involves nearly 108,000 shares, whereas the combined package for the two other employees totals 8,400 shares. This structure is typical for executive-level inducements where regulatory leadership is critical for a commercial-stage biotechnology company like Vera Therapeutics, which markets TRUTAKNA™ (atacicept-vymj) for autoimmune diseases.
How might the appointment of a new Chief Regulatory Officer influence Vera Therapeutics' pipeline approval timelines for TRUTAKNA and other candidates?
What impact could the dilution from these new equity grants have on existing shareholders, particularly given the specific vesting schedules outlined?
Does the significant disparity in equity compensation between Dr. Bowman and other new hires signal a strategic pivot toward regulatory expertise over operational or commercial roles?
15
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
